Skip to main content
. 2017 Jan 10;40(4):333–341. doi: 10.1007/s40264-016-0501-2

Fig. 2.

Fig. 2

Characteristics of the patient populations. a Distribution of patients enrolled in the lenalidomide and thalidomide Risk Evaluation and Mitigation Strategies (REMS) programs between June 2012 and June 2013 by risk category (N = 73,645). b Distribution of patients in the voluntary survey population by risk category (N = 2790). C Proportion of patients in the voluntary survey population who received and read the patient education brochure by risk category